Astellas Pays $300m+ For iota In ‘Pharma-Plus’ Push
Sees Magic In ‘Neural Dust’ Implant Tech
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.